Endostatin ELISA Assay Kit

$570.00

The Eagle Biosciences Endostatin ELISA Assay KIT(enzyme-linked immunoassay kit) is intended for the quantitative determination of human Endostatin in plasma and serum. The Eagle Biosciences Endostatin ELISA Assay KIT is manufactured by Biomedica (www.bmgrp.com).  The Endostatin ELISA Assay KIT is for research use only and not to be used in diagnostic procedures.

SKU: BI-20742 Categories: ,

Endostatin ELISA Assay Kit

For Research Use Only

Size: 1×96 wells
Sensitivity: 0.2 nmol/L
Dynamic Range: 5 – 80 nmol/L
Incubation Time: 4.5 hours
Sample Type: plasma, serum
Sample Size: 20 µL

Controls Included

Conversion Factor: ng/ml to nmol/l:  1 ng/ml = 0.05 nmol/l (MW: 20 kDa)
Validated for studies of Humans and Rat/Mice.
Product Developed and Manufactured in Austria by Biomedica


Learn more about Endostatin and Endostatin Related Studies here:

Endostatin Biomarker Spotlight 

Endostatin Human and Rat/Mice Studies

Additional Information

Assay Background

Endostatin, a 20-kDa C-terminal proteolytic fragment of collagen XVIII, is an endogenous angiogenesis inhibitor localized in the vascular basement membrane in various organs.  The biological functions of the endostatin-network involve SPARC, thrombospondin-1, glycosaminoglycans, collagens, and integrins.   Endostatin is expressed during the progression of renal fibrosis in tubular cells of injured tissue. In renal micro-vascular disease, observed in late stages of patients with chronic kidney disease, increased endostatin levels are possibly the consequence of enhanced extracellular matrix degradation. Thus endostatin may become an important marker for progressive microvascular renal disease in patients with chronic kidney disease. Endostatin levels in blood are also likely to increase in patients with other microvascular tissue injuries, including atherosclerosis, myocardial- and brain ischemia. In ischemic stroke patients, high endostatin plasma levels predict a worse long-term clinical outcome.

Assay Principle

  • All reagents and samples have to be brought to room temperature (18-26°C) before they can be used in the Endostatin ELISA Assay Kit.
  • Mark position for BLANK/STD/SAMPLE/CTRL (Blank/Standard/Sample/Control) on the protocol sheet.
  • Take microtiter strips out of the aluminium bag, reserve a minimum of one well as blank. Unused strips can be stored with desiccant in the aluminium bag at +4°C (2-8°C) until the expiry date.
  1. Pipette 100 µl ASYBUF (Assay Buffer, natural cap) into each well. Pipette additional 100 µl into well marked as blank.
  2. Add 20 µl of 1+100 diluted STD/SAMPLE/CTRL (Standard/Sample/Control) in duplicate into respective well, except blank.
  3. Add 50 µl AB (Antibody) into each well, swirl gently.
  4. Cover tightly and incubate 3 hours at room temperature (18-26°C).
  5. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer). After final wash, remove remaining WASHBUF by strongly tapping plate against paper towel.
  6. Add 200 µl CONJ (Conjugate, amber cap) into each well.
  7. Cover tightly and incubate for 1 hour at room temperature (18-26°C).
  8. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer). After final wash, remove remaining WASHBUF by strongly tapping plate against paper towel.
  9. Add 200 µl SUB (Substrate, blue cap) into each well.
  10. Incubate for 30 min at room temperature (18-26°C) in the dark.
  11. Add 50 µl STOP (Stop solution, white cap) into each well.
  12. Measure absorbance immediately at 450 nm with reference 630 nm, if available.

Standard Curve

Manual

Product Manual


Publications

References:

  • Elevated plasma levels of endostatin are associated with chronic kidney disease. Chen et al., 2012, Am J Nephrol 35(4): 335-340.
  • Early-onset coronary artery disease after pediatric kidney transplantation: implicating the angiogenesis inhibitor, endostatin. Igbal CW et al., 2011, Am Surg 77(6): 731-735.
  • A defective angiogenesis in chronic kidney disease. Futrakul N et al., 2008, Ren Fail 30(2): 215-217.
  • Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction. Moskowitz-Kassai E et al., 2012, Nephrol Dial Transplant 27(2): 494-497.
  • Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Sodha NR et al., 2009, Am J Physiol Heart Circ Physiol, 296: H428-H434.
  • A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Navarro-Sobrino M et al., 2011, Atherosclerosis, 216(1): 205-211.